Hey everyone hope someone with a little more insight can help me here.
I'm wondering why the stage 5 trial didn't work out. The prospectus seems to blame one of the biomarkers not performing as expected.
I can see there's a lot of collaboration with CSIRO to develop the final biomarker / antibodies and confirm that they can be sustainably produced (supply chain control).
Again from the prospectus and a recent announcement I can see that stage 6 will apply the new biomarker / antibodies to the samples from stage 5 trial to confirm success. At the same time stage 7 (1000 person trial) will begin to be organised concurrently to save time.
Does someone have a handle on, or has spoken to the company about why stage 5 trial didn't work out specifically and why they are confident that the new biomarker developed by CSIRO will succeed when applied to stage 5 samples?
Obviously they're trying to keep the timeline going though if the new biomarker from CSIRO doesn't work as expected when they apply it to the stage 5 samples to confirm success, then timelines will be pushed out quite a lot as the stage 7 trial will need to be pushed back.
Any thoughts would be welcome. I've read the research note shared in the thread though I don't believe it addressed this series of questions.
Cheers
New Feature Announcement!
We’re excited to introduce the DealRoom portal, now live on site, providing users with exciting access to private equity opportunities for both pre-IPO and publicly listed companies.
See full details by selecting the new menu item named 'DealRoom' on our main menu bar or click below.
Stay ahead of the market, with HotCopper.